Michael B Levy1, Arnon Elizur2, Michael R Goldberg1, Liat Nachshon1, Yitzhak Katz3. 1. Allergy and Immunology Institute, Assaf-Harofeh Medical Center, Tel Aviv, Israel. 2. Allergy and Immunology Institute, Assaf-Harofeh Medical Center, Tel Aviv, Israel; Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Allergy and Immunology Institute, Assaf-Harofeh Medical Center, Tel Aviv, Israel; Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: ykatz49@gmail.com.
Abstract
BACKGROUND: Avoidance strategies in patients with cow's milk allergy occasionally fail to protect these patients from inadvertent exposures, leading to life-threatening reactions. OBJECTIVE: To assess the safety and efficacy of milk oral immunotherapy as an alternative therapeutic strategy. METHODS: Patients (n = 280, >4 years old) with IgE-mediated cow's milk allergy were enrolled into a milk oral immunotherapy program at a single hospital center. High-risk patients were not excluded. The treatment protocol consisted of 3 rounds of oral induction performed every 4 weeks. On day 1, a patient's reaction threshold was determined. On days 2 and 3, a tolerated starting dose below the threshold was confirmed. Day 4 mimicked the home treatment, which continued until the next induction. RESULTS: The median initial starting dose was 52.5 mg of cow's milk protein. Excluding those whose treatment failed in the first week (n = 5) or are still undergoing treatment (n = 15), 61.5% (160 of 260 patients) achieved 7,200 mg and 85.4% of patients were consuming at least 180 mg of milk protein. Reactions at home requiring the use of injectable epinephrine occurred in 15.7% of patients (44 of 280) and in 0.075% (58 of 77,098) of doses administered. Predictors for achieving a full dose in multivariate analysis included a starting dose higher than 30 mg of milk protein (odds ratio 4.6, P < .001), not requiring epinephrine during induction (odds ratio 5.2, P < .001) or home treatment (odds ratio 2.6, P = .037), and the lack of nonanaphylactic type symptoms (odds ratio 15.6, P < .001). CONCLUSION: Milk oral immunotherapy, carried out in a highly controlled setting, is successful in protecting the overwhelming majority of patients from accidental exposures to cow's milk protein.
BACKGROUND: Avoidance strategies in patients with cow's milk allergy occasionally fail to protect these patients from inadvertent exposures, leading to life-threatening reactions. OBJECTIVE: To assess the safety and efficacy of milk oral immunotherapy as an alternative therapeutic strategy. METHODS:Patients (n = 280, >4 years old) with IgE-mediated cow's milk allergy were enrolled into a milk oral immunotherapy program at a single hospital center. High-risk patients were not excluded. The treatment protocol consisted of 3 rounds of oral induction performed every 4 weeks. On day 1, a patient's reaction threshold was determined. On days 2 and 3, a tolerated starting dose below the threshold was confirmed. Day 4 mimicked the home treatment, which continued until the next induction. RESULTS: The median initial starting dose was 52.5 mg of cow's milk protein. Excluding those whose treatment failed in the first week (n = 5) or are still undergoing treatment (n = 15), 61.5% (160 of 260 patients) achieved 7,200 mg and 85.4% of patients were consuming at least 180 mg of milk protein. Reactions at home requiring the use of injectable epinephrine occurred in 15.7% of patients (44 of 280) and in 0.075% (58 of 77,098) of doses administered. Predictors for achieving a full dose in multivariate analysis included a starting dose higher than 30 mg of milk protein (odds ratio 4.6, P < .001), not requiring epinephrine during induction (odds ratio 5.2, P < .001) or home treatment (odds ratio 2.6, P = .037), and the lack of nonanaphylactic type symptoms (odds ratio 15.6, P < .001). CONCLUSION: Milk oral immunotherapy, carried out in a highly controlled setting, is successful in protecting the overwhelming majority of patients from accidental exposures to cow's milk protein.
Authors: Betty C A M van Esch; Suzanne Abbring; Mara A P Diks; Gemma M Dingjan; Lucien F Harthoorn; A Paul Vos; Johan Garssen Journal: Immun Inflamm Dis Date: 2016-03-24
Authors: Antonio Bognanni; Derek K Chu; Ramon T Firmino; Stefania Arasi; Siw Waffenschmidt; Arnav Agarwal; Piotr Dziechciarz; Andrea Horvath; Rime Jebai; Hanako Mihara; Yetiani Roldan; Maria Said; Raanan Shamir; Martin Bozzola; Sami Bahna; Alessandro Fiocchi; Susan Waserman; Holger J Schünemann; Jan L Brożek Journal: World Allergy Organ J Date: 2022-09-08 Impact factor: 5.516
Authors: P Bégin; E S Chan; H Kim; M Wagner; M S Cellier; C Favron-Godbout; E M Abrams; M Ben-Shoshan; S B Cameron; S Carr; D Fischer; A Haynes; S Kapur; M N Primeau; J Upton; T K Vander Leek; M M Goetghebeur Journal: Allergy Asthma Clin Immunol Date: 2020-03-18 Impact factor: 3.406
Authors: Liat Nachshon; Michael R Goldberg; Michael B Levy; Naama Epstein-Rigbi; Yael Koren; Arnon Elizur Journal: Ann Allergy Asthma Immunol Date: 2021-05-16 Impact factor: 6.248